QT VASCULAR LTD.

(Company Registration No. 201305911K)

(Incorporated in Singapore)

RESPONSE FROM THE SGX-REGCO IN RELATION TO ENQUIRY ON APPLICATION OF CHAPTER 4 AND RULES 1307, 1308 AND 1309 OF THE CATALIST RULES IN RELATION TO THE COMPANY'S PROPOSED CORPORATE RESTRUCTURING BY WAY OF A SCHEME OF ARRANGEMENT ("PROPOSED SCHEME")

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the Company's announcement dated 25 May 2021.

Further to the announcement by the Company dated 25 May 2021 in relation to the Proposed Transactions by way of the Proposed Scheme, the Board of Directors ("Directors") of the Company wishes to announce that the Company had on 16 November 2021 received guidance from the Singapore Exchange Regulation Pte Ltd ("SGX-Regco") that the listing and delisting requirements under Chapter 4 and Rules 1307, 1308 and 1309 of the Catalist Rules are not applicable to the Proposed Scheme, subject to the following conditions being met:

(a) the Company's compliance with the SGX-ST's listing requirements;

(b) announcement of the implementation of the Proposed Scheme and the fulfilment of the conditions precedent;

(c) approval being obtained from Shareholders and the relevant authorities for the Proposed Scheme;

(d) sanction of the Proposed Scheme by the High Court of Singapore;

(e) submission of an undertaking (in the form set out in Appendix 7H of the Catalist Rules) from each of the directors and executive officers of NewCo to comply with the Catalist Rules; and

(f) submission of an undertaking from the Company that any subsequent disposal of the Company's current business is subject to shareholders' approval.

Shareholders should note that the response from the SGX-Regco is not to be taken as an indication of the merits of the Proposed Scheme, NewCo shares, NewCo, the Company and/or its subsidiaries. The SGX-Regco also reserves the right to amend and/or vary its response, which is subject to changes in the SGX-Regco's policies.

SHAREHOLDERS AND OTHER INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY AS THERE IS NO CERTAINTY OR ASSURANCE THAT THE PROPOSED SCHEME WILL BE COMPLETED. THIS IS ESPECIALLY IN VIEW OF THE RECEIPT BY THE COMPANY OF THE NOTICE OF INTENTION TO CALL FOR AN EXTRAORDINARY GENERAL MEETING BY CERTAIN SHAREHOLDERS AS ANNOUNCED ON 16 NOVEMBER 2021 AND SUBSEQUENT DESPATCH OF THE CIRCULARS BY SAID SHAREHOLDERS ON 17 NOVEMBER 2021.

SHAREHOLDERS AND OTHER INVESTORS ARE ADVISED TO READ ANY ANNOUNCEMENTS BY THE COMPANY CAREFULLY. THEY SHOULD CONSULT THEIR STOCKBROKERS, BANK MANAGERS, SOLICITORS, ACCOUNTANTS, TAX ADVISORS OR OTHER PROFESSIONAL ADVISORS IF THEY ARE IN ANY DOUBT AS TO THE ACTIONS THEY SHOULD TAKE.

By Order of the Board of Directors
QT VASCULAR LTD.

Eitan Konstantino
Chief Executive Officer and Executive Director
18 November 2021

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.